Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Neuroptis Biotech Announces the Preclinical Results for its Dry Eye Product ML7

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
Human clinical trials are planned for mid 2014.

Neuroptis Biotech has announced positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

The candidate molecule, ML7, is the first in a new therapeutic class. It has the potential to bring an effective, targeted therapeutic response to the millions of people who suffer from dry eye syndromes.

This can affect patients' lachrymal apparatus, manifesting as insufficient quality or quantity of tears and a feeling of dry eyes.

The syndrome may be idiopathic, or it may be associated with allergies, inflammation of the anterior segment or Gougerot-Sjogren syndrome. It may also occur following cataract surgery.

Studies in animals have shown excellent local tolerance of the product, very low systemic absorption (less than one per cent) and superior efficacy to the placebo, which uses the same eye drops, but without the ML7.

In the preclinical trials ML7 was used in the form of preservative-free, stable eye drops in single-unit doses.

The preclinical results were published in the medical journal IOVS (Investigative Ophthalmology and Visual Science):
http://www.iovs.org/content/early/2013/03/20/iovs.12-10193.abstract?papetoc.

"The completion of preclinical work and studies marks the culmination of efforts by the team at Neuroptis Biotech and their partners, Provence Technologies, Octalia, Cerep and Iris Pharma," said Dr Eric Belot, CEO of Neuroptis Biotech. "We will start phases I and II in the next few months, as soon as the EMA has given its approval for trials on human subjects.”

Treatment for dry eye syndromes is a growth market with an estimated value of USD 1.2 billion worldwide. The company will begin production of clinical batches to launch the clinical trials through a subcontractor.

They will also submit the requisite applications for approval by the European Medicines Agency (EMA) and local patient protection committees.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
How Cancer Spreads in the Body
Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London.
Rates of Nonmedical Prescription Opioid Use Disorder Double in 10 Years
Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
‘Human-on-a-Chip’ Could Replace Animal Testing
Researchers are developing a “human-on-a-chip,” a miniature external replication of the human body, integrating biology and engineering with a combination of microfluidics and multi-electrode arrays.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
‘Missing Tooth’ Hydrogels Handle Hard-to-Deliver Drugs
Rice University’s custom hydrogel traps water-avoiding molecules for slow delivery.
Copper is Key in Burning Fat
Berkeley Lab scientist says results could provide new target for obesity research.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!